Author

V. Sepe

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Assay:metabolomics· 1 Organism:mouse· 1

Frequent Co-Authors

A. Zampella· 4 shared E. Distrutti· 4 shared M. Biagioli· 4 shared S. Fiorucci· 4 shared B. Catalanotti· 3 shared A. Carino· 2 shared A. Donini· 2 shared B. Fiorillo· 2 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

A. Zampella

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

A microbial derived bile acid acts as GPBAR1 agonist and RORγt inverse agonist and reverses inflammation in inflammatory bowel disease

M. Biagioli, C. Di Giorgio, C. Massa, S. Marchiano', R. Bellini, M. Bordoni, G. Urbani, R. Roselli, G. Lachi, E. Morretta, F. Dal Piaz, B. Charlier, B. Fiorillo, B. Catalanotti, L. Cari, , S. Fiorucci

This study identifies 3-oxo-DCA as a microbial bile acid that acts as a GPBAR1 agonist and RORγt inverse agonist, reversing inflammation in IBD.

bioRxiv · Apr 8, 2024 · PreprintImmunology

Bile Acids Serve As Endogenous Antagonists Of The Leukemia Inhibitory Factor (LIF) Receptor in Oncogenesis

C. Di Giorgio, E. Morretta, A. Lupia, R. Bellini, C. Massa, G. Urbani, M. Bordoni, S. Marchiano, P. Rapacciuolo, C. Finamore, V. Sepe, M. C. Monti, F. Monarca, N. Natalizi, L. Graziosi, , S. Fiorucci

The paper shows bile acids, specifically GDCA, inhibit LIFR in gastric cancer, suggesting potential for bile acid-based therapies in LIF-driven oncogenesis.

bioRxiv · Sep 30, 2023Cancer Biology

Analysis of gastric cancer transcriptome allows the identification of histotype specific molecular signatures with prognostic potential

A. Carino, L. Graziosi, S. Marchiano, M. Biagioli, E. Marino, V. Sepe, A. Zampella, E. Distrutti, A. Donini, S. Fiorucci

This study identifies histotype-specific molecular signatures in gastric cancer using transcriptomic analysis, finding AQP9, CARD14, and CXCR2 as prognostic markers.

bioRxiv · Feb 2, 2021Cancer Biology

Hijacking SARS-Cov-2/ACE2 receptor interaction by natural and semi-synthetic steroidal agents acting on functional pockets on receptor binding region

A. Carino, F. Moraca, B. Fiorillo, S. Marcano, V. Sepe, M. Biagioli, C. Finamore, S. Bozza, D. Francisci, E. Distrutti, B. Catalanotti, A. Zampella, S. Fiorucci

This study identifies steroidal agents that inhibit SARS-CoV-2 entry by targeting binding pockets on the Spike protein's receptor-binding domain.

bioRxiv · Jun 10, 2020Pharmacology & Toxicology